Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroids Treatment for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients
NCT07116811Phase 3Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylprednisolone sodium succinate and prednisone acetate in facial nerve paralysis (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Proportion of patients with good facial nerve function recovery (House-Brackmann grade I or II) at 90 days. Started Oct 2025; status: recruiting.
02
Drugs
methylprednisolone sodium succinateprednisone acetate
03
Conditions
facial nerve paralysis
Beyond the preview
Go deeper on NCT07116811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116811.